1. Home
  2. XP vs PRAX Comparison

XP vs PRAX Comparison

Compare XP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XP Inc.

XP

XP Inc.

HOLD

Current Price

$19.55

Market Cap

10.9B

Sector

Finance

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$328.80

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XP
PRAX
Founded
2001
2015
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
9.6B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
XP
PRAX
Price
$19.55
$328.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
15
Target Price
$23.17
$572.13
AVG Volume (30 Days)
5.2M
345.4K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
0.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.00
N/A
Revenue Next Year
$13.64
$7,758.26
P/E Ratio
$11.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.51
$34.89
52 Week High
$23.13
$354.87

Technical Indicators

Market Signals
Indicator
XP
PRAX
Relative Strength Index (RSI) 47.74 53.49
Support Level $18.58 $282.49
Resistance Level $20.42 $353.83
Average True Range (ATR) 0.75 16.69
MACD 0.03 1.67
Stochastic Oscillator 37.45 55.97

Price Performance

Historical Comparison
XP
PRAX

About XP XP Inc.

XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: